Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in inflammatory and neuropathic pain models and to potently inhibit angiogenesis and tumor growth in in vitro assays.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 μg | 約 35 days | ¥ 22,500 |
50 μg | 約 35 days | ¥ 45,000 |
100 μg | 約 35 days | ¥ 83,500 |
500 μg | 約 35 days | ¥ 367,500 |
説明 | Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human serum, and acts as a substrate for soluble epoxide hydrolase with a Km value of 5.1 μM. (±)10(11)-EpDPA and other epoxy metabolites of DHA are reported to demonstrate antihyperalgesic activity in inflammatory and neuropathic pain models and to potently inhibit angiogenesis and tumor growth in in vitro assays. |
分子量 | 344.495 |
分子式 | C22H32O3 |
CAS No. | 895127-65-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 50 mg/mL
DMF: 25 mg/mL
DMSO: 20 mg/mL
Ethanol:PBS(pH 7.2) (1:1): 0.5 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
(±)10(11)-EpDPA 895127-65-8 (±)10(11)EpDPA (±)10(11) EpDPA 10(11)-EpDPA Inhibitor inhibitor inhibit